10:29 AM
 | 
Nov 18, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Inclisiran: Additional Ph II ORION-1 data

Additional data from the double-blind, international Phase II ORION-1 trial in 497 patients with atherosclerotic cardiovascular disease or atherosclerotic cardiovascular disease-risk equivalents and elevated LDL-C despite receiving maximum tolerated doses of LDL-C-lowering therapies showed that a single injection of 300 mg subcutaneous inclisiran reduced mean LDL-C from baseline to day 60 by 51%...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >